Friday, July 10, 2026

pharma · Melanoma · HIV Infections

Bristol Myers Squibb

Bristol-Myers Squibb is a pharma organization headquartered in STEINHAUSEN, CH. Primary therapeutic focus areas include Melanoma, HIV Infections, Prostate Cancer, Neoplasms by Site, Stomach Cancer. NovaPharmaNews links 4

3401 Princeton Pike, Lawrence Township, NJ 08648, US HQ
38,146 Employees
NMPA registrant Type
Company details
Clinical program

Daclatasvir

Phase 3 · small molecule · Hepatitis C Virus Infection

Daclatasvir for Hepatitis C Virus Infection is a Phase 3 program (small_molecule) at Bristol-Myers Squibb with 2 ClinicalTrials.gov record(s).

← All Bristol-Myers Squibb projects Phase 3 small molecule completed

Internal code AI444-026

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Bristol-Myers Squibb
Phase
Phase 3
Modality
small_molecule
Indication
Hepatitis C Virus Infection
Status
completed
Trials
2